Due to millions of years of coevolution, humans count on our gut bacteria to maintain our health.
Stellate Therapeutics uses the human microbiome as a source of small molecule therapies for devastating diseases, starting with neurological disorders.
Our lead candidate, STL-101 is a potential first-in-class, disease-modifying therapy for Parkinson’s and Alzheimer’s disease.
Nicole McKnight PhD
CEO
David Immke PhD
CSO
Patrice Garnier PhD
President
Antoine Danchin PhD
Scientific Founder
Bernard Munos MBA, MS
Robert Schneider PhD
Alexandre Mouradian
Eric Fourmentin
Nicole McKnight PhD
CEO
David Immke PhD
CSO
Jonathan Weiss PhD, MBA
Director, Business Development
Patricia Richard PhD
Director, Neuroscience
Xavier Manière PharmD, PhD
Director, Discovery Biology
Sabriya Stukes PhD
Operations Director
Géraldine Androdias MD
Sahar El Aidy PhD
Michael Spedding PhD